Back
Ultragenyx Pharmaceutical Inc (RARE)
BiotechnologyRARE · NASDAQ NMS - GLOBAL MARKET · USD
New to investing? How to read this page →$15.49
+1.44%Weekly undervalued picks
Price · 1 year
Loading live analysis…
Loading analysis…
Intrinsic Investor is for research and education only. Not financial advice.
Key metrics
EPS
$-5.83
ROE
Gross margin
-28.1%
Debt/Equity
Revenue growth
-2.2%
P/B ratio
Beta
Forward P/E
Ultragenyx Pharmaceutical Inc — company intelligence
Earnings surprises
Q2 2026$-0.90 vs $-1.24 est+27.4%
Q1 2026$-1.84 vs $-1.54 est-19.5%
Q4 2025$-1.29 vs $-1.11 est-15.8%
Q3 2025$-1.81 vs $-1.26 est-43.7%
Analyst consensus · 26 analysts
23 Buy3 Hold0 Sell
Updated Oct 10, 2026
Insider activity · 90 days
0 buys2 sellsnet -6,596 shares
Horn HowardSell 4,696 · Aug 3, 2026
Parschauer Karah HerdmanSell 1,900 · Aug 3, 2026
Recent SEC filings
8-K — Material event reportSep 17, 2026
4 — Insider transaction reportSep 15, 2026
4 — Insider transaction reportSep 8, 2026
Latest news
FDA review docs spark Revolution sell-off; Zealand diabetes data underwhelm analysts — Yahoo · 1d ago
Is Ultragenyx Pharmaceutical (RARE) Undervalued Following EMA Validation For Its Sanfilippo Gene Therapy? — Yahoo · 2d ago
AI Valuation Narrative
Generates a short bull / bear / catalyst summary from the analytics we already computed. No target prices. Research tool, not investment advice.
Explore more
Peers & similar stocks
Quick links to related tickers for research.
Weekly undervalued picks
Get 3 new value ideas and the fair-value math behind them every week. One email, unsubscribe anytime.
Free. No spam. We only email once per week.
Data is provided "as-is" and may be delayed or incomplete. Intrinsic Investor is for education only and is not investment advice.